NCT02895906View on ClinicalTrials.gov

Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 28, 2016

Primary Completion Date

April 13, 2017

Study Completion Date

April 20, 2017

Conditions
22q11.2 Deletion Syndrome
Interventions
DRUG

NFC-1

Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard gelatin capsules for oral administration.

Trial Locations (1)

19104

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
lead

Aevi Genomic Medicine, LLC, a Cerecor company

INDUSTRY

NCT02895906 - Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions | Biotech Hunter | Biotech Hunter